David J. Grainger - Sep 30, 2022 Form 4/A - Amendment Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Sep 30, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
11/23/2022, 04:05 PM
Date Of Original Report
Oct 4, 2022
Previous filing
Jul 6, 2022
Next filing
Jan 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CNTA Ordinary Shares 914K Sep 30, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The transactions previously reported on the Form 4 filed on October 4, 2022 were canceled in their entirety before settlement by the broker without instruction from the Issuer or Reporting Person.